Skip to main content
SpringerLink
Log in

Modern Malaria Chemoprophylaxis

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Currently available medications for malaria chemoprophylaxis are efficacious but the problems of patient compliance, the advance of parasite drug resistance, and real or perceived serious adverse effects mean that new chemical compounds are needed.

Primaquine, which has been widely used to treat relapsing malaria since the 1950s, has been shown to prevent malaria when taken daily. Tafenoquine is a new 8-aminoquinoline with a much longer half-life than primaquine. Field trials to date indicate that tafenoquine is efficacious and can be taken weekly or perhaps even less frequently. Both primaquine and tafenoquine require exact knowledge of a person’s glucose 6-phosphate dehydrogenase status in order to prevent drug-induced haemolysis. Other potential malaria chemoprophylactic drugs such as third-generation antifol compounds and Mannich bases have reached advanced preclinical testing. Mefloquine has been seen to cause serious neuropsychiatric adverse effects on rare occasions. Recent public controversy regarding reputedly common serious adverse effects has made many Western travellers unwilling to take mefloquine.

Special risk groups exposed to malaria, such as long-term travellers, children, pregnant women, aircrew and those requiring unimpeded psychomotor reactions, migrants returning to visit malarious countries of origin and febrile persons who have returned from malaria endemic areas, all require a nuanced approach to the use of drugs to prevent malaria. The carrying of therapeutic courses of antimalarial drugs to be taken only if febrile illness develops is indicated in very few travellers despite its appeal to some who fear adverse effects more than they fear potentially lethal malaria infection. Travellers with a significant exposure to malaria require a comprehensive plan for prevention that includes anti-mosquito measures but which is still primarily be based on the regular use of efficacious antimalarial medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6(4): 861–71

    Article  PubMed  CAS  Google Scholar 

  2. Ward SA, Bray PG. Definitive proof for a role of pfmdr 1 in quinoline resistance in Plasmodium falciparum. Drug Resist Updat 2000; 3(2): 80–1

    Article  PubMed  CAS  Google Scholar 

  3. Bray PG, Janneh O, Raynes KJ, et al. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J Cell Biol 1999; 145(2): 363–76

    Article  PubMed  CAS  Google Scholar 

  4. Warhurst DC, Craig JC, Adagu IS. Lysosomes and drug resistance in malaria. Lancet 2002; 360(9345): 1527–9

    Article  PubMed  Google Scholar 

  5. McCutchan TF, Welsh JA, Dame JB, et al. Mechanism of pyrimethamine resistance in recent isolates of Plasmodium falciparum. Antimicrob Agents Chemother 1984; 26(5): 656–9

    Article  PubMed  CAS  Google Scholar 

  6. Cowman AF, Morry MJ, Biggs BA, et al. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 1988; 85(23): 9109–13

    Article  PubMed  CAS  Google Scholar 

  7. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 1988; 85(23): 9114–8

    Article  PubMed  CAS  Google Scholar 

  8. Triglia T, Menting JG, Wilson C, et al. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 1997; 94(25): 13944–9

    Article  PubMed  CAS  Google Scholar 

  9. Basco LK, Tahar R, Ringwald P. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother 1998; 42(7): 1811–4

    PubMed  CAS  Google Scholar 

  10. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54(1): 62–6

    PubMed  CAS  Google Scholar 

  11. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 2003; 37(3): 450–1

    Article  PubMed  Google Scholar 

  12. Korsinczky M, Chen N, Kotecka B, et al. Mutations in plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000; 44(8): 2100–8

    Article  PubMed  CAS  Google Scholar 

  13. Wichmann O, Muehlen M, Gruss H, et al. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J 2004; 3(1): 14

    Article  PubMed  Google Scholar 

  14. Newman RD, Parise ME, Barber AM, et al. Malaria-related deaths among US travelers, 1963–2001. Ann Intern Med 2004; 141(7): 547–55

    PubMed  Google Scholar 

  15. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39(9): 1336–45

    Article  PubMed  CAS  Google Scholar 

  16. Baird JK, Lacy MD, Basri H, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 2001; 33(12): 1990–7

    Article  PubMed  CAS  Google Scholar 

  17. Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria for nonimmune travelers: a comparison with mefloquine and doxycycline. Clin Infect Dis 1999; 29(6): 1502–6

    Article  PubMed  CAS  Google Scholar 

  18. Fryauff DJ, Baird JK, Purnomo, et al. Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. Am J Trop Med Hyg 1997; 56(2): 137–40

    PubMed  CAS  Google Scholar 

  19. Baird JK, Fryauff DJ, Basri H, et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 1995; 52(6): 479–84

    PubMed  CAS  Google Scholar 

  20. Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003; 37(12): 1659–67

    Article  PubMed  CAS  Google Scholar 

  21. Peters W, Robinson BL, Milhous WK. The chemotherapy of rodent malaria. LI: studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasital 1993; 87(6): 547–52

    CAS  Google Scholar 

  22. Puri SK, Dutta GP. Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys. Acta Trop 2003; 86(1): 35–40

    Article  PubMed  CAS  Google Scholar 

  23. Ponsa N, Sattabongkot J, Kittayapong P, et al. Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. Am J Trop Med Hyg 2003; 69(5): 542–7

    PubMed  CAS  Google Scholar 

  24. Brueckner RP, Lasseter KC, Lin ET, et al. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998; 58(5): 645–9

    PubMed  CAS  Google Scholar 

  25. Walsh DS, Eamsila C, Sasiprapha T, et al. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. J Infect Dis 2004; 190(8): 1456–63

    Article  PubMed  CAS  Google Scholar 

  26. Shanks GD, Oloo AJ, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 2001; 33(12): 1968–74

    Article  PubMed  CAS  Google Scholar 

  27. Hale BR, Owusu-Agyei S, Fryauff DJ, et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 2003; 36(5): 541–9

    Article  PubMed  CAS  Google Scholar 

  28. Lell B, Faucher JF, Missinou MA, et al. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 2000; 355(9220): 2041–5

    Article  PubMed  CAS  Google Scholar 

  29. Nasveld P, Kitchener S, Edstein M, et al. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Trans R Soc Trop Med Hyg 2002; 96(6): 683–4

    Article  PubMed  Google Scholar 

  30. Nasveld P, Brennan L, Edstein M. A randomised, double-blind comparative study to evaluate the safety, tolerability and effectiveness of tafenoquine and mefloquine for the prophylaxis of malaria in non-immune Australian soldiers [abstract no. 326]. Am J Trop Med Hyg 2002; 67(2): 255

    Google Scholar 

  31. Rieckmann K. The in vitro activity of experimental antimalarial compounds against strains of Plasmodium falciparum with varying degrees of sensitivity to pyrimethamine and chloroquine. In: Chemotherapy of malaria and resistance to antimalarials. WHO Technical Report Series, No. 529. Geneva: World Health Organization, 1973: 58

    Google Scholar 

  32. Canfield C. New antimalarials under development. In: Bruce-Chwatt L, editor. Chemotherapy of malaria. Rev. 2nd ed. Monograph series27. Geneva: World Health Organization, 1986: 99–100

    Google Scholar 

  33. Childs GE, Lambros C. Analogues of N-benzyloxydihydrotriazines: in vitro antimalarial activity against Plasmodium falciparum. Ann Trop Med Parasitol 1986; 80(2): 177–81

    PubMed  CAS  Google Scholar 

  34. Fidock DA, Nomura T, Wellems TE. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol 1998; 54(6): 1140–7

    PubMed  CAS  Google Scholar 

  35. Canfield CJ, Milhous WK, Ager AL, et al. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 1993; 49(1): 121–6

    PubMed  CAS  Google Scholar 

  36. Edstein MD, Corcoran KD, Shanks GD, et al. Evaluation of WR250417 (a proguanil analog) for causal prophylactic activity in the Plasmodium cynomolgi-Macaca mulatta model. Am J Trop Med Hyg 1994; 50(2): 181–6

    PubMed  CAS  Google Scholar 

  37. Rieckmann KH, Yeo AE, Edstein MD. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans R Soc Trop Med Hyg 1996; 90(5): 568–71

    Article  PubMed  CAS  Google Scholar 

  38. Jensen NP, Ager AL, Bliss RA, et al. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J Med Chem 2001; 44(23): 3925–31

    Article  PubMed  CAS  Google Scholar 

  39. Schiehser G, Shieh H-M, Nevchas I. Selection of the third generation antifolate, JPC-2056, as a pre-clinical development candidate [abstract no. 727]. Am J Trop Med Hyg 2004; 71(4): 215

    Google Scholar 

  40. Rwagacondo CE, Niyitegeka F, Sarushi J, et al. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg 2003; 68(6): 743–7

    PubMed  CAS  Google Scholar 

  41. Abacassamo F, Enosse S, Aponte JJ, et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health 2004; 9(2): 200–8

    Article  PubMed  CAS  Google Scholar 

  42. Hatten CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; I(8478): 411–4

    Article  Google Scholar 

  43. Neftel KA, Woodtly W, Schmid M, et al. Amodiaquine induced agranulocytosis and liver damage. BMJ (Clin Res Ed) 1986; 292(6522): 721–3

    Article  CAS  Google Scholar 

  44. O’Neill PM, Mukhtar A, Stocks PA, et al. Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J Med Chem 2003; 46(23): 4933–45

    Article  PubMed  CAS  Google Scholar 

  45. Fidock DA, Rosenthal PJ, Croft SL, et al. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004; 3(6): 509–20

    Article  PubMed  CAS  Google Scholar 

  46. Kotecka BM, Barlin GB, Edstein MD, et al. New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amodiaquine, or pyronaridine. Antimicrob Agents Chemother 1997; 41(6): 1369–74

    PubMed  CAS  Google Scholar 

  47. Sweeney T, Pick R. 4-Aminoquinolines and Mannich Bases. New York: Springer-Verlag, 1984

    Google Scholar 

  48. Andersen SL, Oloo AJ, Gordon DM, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 1998; 26(1): 146–50

    Article  PubMed  CAS  Google Scholar 

  49. Anderson SL, Berman J, Kuschner R, et al. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med 1995; 123(10): 771–3

    PubMed  CAS  Google Scholar 

  50. Rouveix B, Coulombel L, Aymard JP, et al. Amodiaquine-induced immune agranulocytosis. Br J Haematol 1989; 71(1): 7–11

    Article  PubMed  CAS  Google Scholar 

  51. Larrey D, Castot A, Pessayre D, et al. Amodiaquine-induced hepatitis: a report of seven cases. Ann Intern Med 1986; 104(6): 801–3

    PubMed  CAS  Google Scholar 

  52. Sowunmi A, Falade CO, Oduola AM, et al. Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1998; 92(4): 446–8

    Article  PubMed  CAS  Google Scholar 

  53. Sudden death in a traveller following halofantrine administration: Togo, 2000. Can Commun Dis Rep 2001; 27(14): 120–1, 124

    Google Scholar 

  54. Hutchinson DB, Whiteman PD, Farquhar JA. Agranulocytosis associated with maloprim: review of cases. Hum Toxicol 1986; 5(4): 221–7

    Article  PubMed  CAS  Google Scholar 

  55. Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35(3): 451–8

    PubMed  CAS  Google Scholar 

  56. Bruce-Chwatt LJ. Quinine and the mystery of blackwater fever. Acta Leiden 1987; 55: 181–96

    PubMed  CAS  Google Scholar 

  57. Genovese RF, Newman DB, Brewer TG. Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol Biochem Behav 2000; 67(1): 37–44

    Article  PubMed  CAS  Google Scholar 

  58. Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992–1998: a review. J Travel Med 1999; 6(2): 122–33

    Article  PubMed  CAS  Google Scholar 

  59. Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341(8849): 848–51

    Article  PubMed  CAS  Google Scholar 

  60. Sanchez JL, DeFraites RF, Sharp TW, et al. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet 1993; 341(8851): 1021–2

    Article  PubMed  CAS  Google Scholar 

  61. Barrett PJ, Emmins PD, Clarke PD, et al. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996; 313(7056): 525–8

    Article  PubMed  CAS  Google Scholar 

  62. Jaspers CA, Hopperus Buma AP, van Thiel PP, et al. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996; 55(2): 230–4

    PubMed  CAS  Google Scholar 

  63. Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004; 27(3): 203–13

    Article  PubMed  CAS  Google Scholar 

  64. Peragallo MS, Sabatinelli G, Sarnicola G. Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military). Trans R Soc Trop Med Hyg 1999; 93(1): 73–7

    Article  PubMed  CAS  Google Scholar 

  65. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341(8856): 1299–303

    Article  PubMed  CAS  Google Scholar 

  66. Schlagenhauf P, Lobel H, Steffen R, et al. Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg 1997; 56(2): 235–40

    PubMed  CAS  Google Scholar 

  67. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993; 44(3): 257–65

    PubMed  CAS  Google Scholar 

  68. Croft AM, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg 1997; 91(2): 199–203

    Article  PubMed  CAS  Google Scholar 

  69. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126(12): 963–72

    PubMed  CAS  Google Scholar 

  70. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33(7): 1015–21

    Article  PubMed  CAS  Google Scholar 

  71. van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002; 72(3): 294–301

    Article  PubMed  CAS  Google Scholar 

  72. Schlagenhauf P, Tschopp A, Johnson R, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003; 327(7423): 1078

    Article  PubMed  Google Scholar 

  73. Kain KC, MacPherson DW, Kelton T, et al. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ 2001; 164(5): 654–9

    PubMed  CAS  Google Scholar 

  74. Weiss SM, Benwell K, Cliffe IA, et al. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson’s disease. Neurology 2003; 61 (11 Suppl. 6): S101–6

    Article  PubMed  CAS  Google Scholar 

  75. FDA requires warnings on anti-malaria drug Lariam. Consum Rep 2004; 69 (1): 45

    Google Scholar 

  76. Medication guide: Lariam® [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2003/LariamMedGuide.pdf [Accessed 2005 Jun 29]

  77. Farquharson L, Noble LM, Barker C, et al. Health beliefs and communication in the travel clinic consultation as predictors of adherence to malaria chemoprophylaxis. Br J Health Psychol 2004; 9(Pt 2): 201–17

    Article  PubMed  Google Scholar 

  78. Reid AJ, Whitty CJ, Ayles HM, et al. Malaria at Christmas: risks of prophylaxis versus risks of malaria. BMJ 1998; 317(7171): 1506–8

    Article  PubMed  CAS  Google Scholar 

  79. Muehlberger N, Jelinek T, Schlipkoeter U, et al. Effectiveness of chemoprophylaxis and other determinants of malaria in travellers to Kenya. Trop Med Int Health 1998; 3(5): 357–63

    Article  PubMed  CAS  Google Scholar 

  80. Lessells R, Jones ME, Welsby PD. A malaria outbreak following a British military deployment to Sierra Leone. J Infect 2004; 48(2): 209–10

    Article  PubMed  Google Scholar 

  81. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, et al. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2(4): 209–18

    Article  PubMed  CAS  Google Scholar 

  82. Hughes C, Tucker R, Bannister B, et al. Malaria prophylaxis for long-term travellers. Commun Dis Public Health 2003; 6(3): 200–8

    PubMed  CAS  Google Scholar 

  83. Blanke CH. Increased malaria-morbidity of long-term travellers due to inappropriate chemoprophylaxis recommendations. Trop Doct 2003; 33(2): 117–9

    PubMed  Google Scholar 

  84. Malaria deaths following inappropriate malaria chemoprophylaxis: United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50(28): 597–9

    Google Scholar 

  85. Knobloch JU. Long-term malaria prophylaxis for travelers. J Travel Med 2004; 11(6): 374–8

    Article  PubMed  Google Scholar 

  86. Hopperus Buma AP, van Thiel PP, Lobel HO, et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996; 173(6): 1506–9

    Article  PubMed  CAS  Google Scholar 

  87. Lobel HO, Varma JK, Miani M, et al. Monitoring for mefloquine-resistant Plasmodium falciparum in Africa: implications for travelers’ health. Am J Trop Med Hyg 1998; 59(1): 129–32

    PubMed  CAS  Google Scholar 

  88. Overbosch D. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. J Travel Med 2003; 10 Suppl. 1: S16–20

    Article  PubMed  Google Scholar 

  89. Stauffer WM, Kamat D, Magill AJ. Traveling with infants and children. Part IV: insect avoidance and malaria prevention. J Travel Med 2003; 10(4): 225–40

    Google Scholar 

  90. Fischer PR, Bialek R. Prevention of malaria in children. Clin Infect Dis 2002; 34(4): 493–8

    Article  PubMed  Google Scholar 

  91. Kramer MH, Lobel HO. Antimalarial chemoprophylaxis in infants and children. Paediatr Drugs 2001; 3(2): 113–21

    Article  PubMed  CAS  Google Scholar 

  92. Camus D, Djossou F, Schilthuis HJ, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004; 38(12): 1716–23

    Article  PubMed  CAS  Google Scholar 

  93. Collee GG, Samra GS, Hanson GC. Chloroquine poisoning: ventricular fibrillation following ‘trivial’ overdose in a child. Intensive Care Med 1992; 18(3): 170–1

    Article  PubMed  CAS  Google Scholar 

  94. Geerligs PD, Brabin BJ, Eggelte TA. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull World Health Organ 2003; 81(3): 205–16

    PubMed  Google Scholar 

  95. Alonzo Gonzalez M, Menendez C, Font F, et al. Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants. Bull World Health Organ 2000; 78(1): 97–107

    PubMed  CAS  Google Scholar 

  96. van Geertruyden JP, Thomas F, Erhart A, et al. The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg 2004; 71 (2 Suppl.): 35–40

    PubMed  Google Scholar 

  97. Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev 2004; 17(4): 760–9

    Article  PubMed  Google Scholar 

  98. Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994; 169(3): 595–603

    Article  PubMed  CAS  Google Scholar 

  99. Nosten F, Vincenti M, Simpson J, et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999; 28(4): 808–15

    Article  PubMed  CAS  Google Scholar 

  100. Smoak BL, Writer JV, Keep LW, et al. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. J Infect Dis 1997; 176(3): 831–3

    Article  PubMed  CAS  Google Scholar 

  101. McGready R, Keo NK, Villegas L, et al. Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Trans R Soc Trop Med Hyg 2003; 97(5): 592–4

    Article  PubMed  CAS  Google Scholar 

  102. McGready R, Stepniewska K, Edstein MD, et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 2003; 59(7): 545–52

    Article  PubMed  CAS  Google Scholar 

  103. Byrne NJ, Behrens RH. Airline crews’ risk for malaria on layovers in urban sub-saharan Africa: risk assessment and appropriate prevention policy. J Travel Med 2004; 11(6): 359–61

    Article  PubMed  Google Scholar 

  104. Chambers JA. Military aviators, special operations forces, and causal malaria prophylaxis. Mil Med 2003; 168(12): 1001–6

    PubMed  Google Scholar 

  105. Barron BA. Chemoprophylaxis in US Naval aircrew transiting malaria endemic areas. Aviat Space Environ Med 1998; 69(7): 656–65

    PubMed  CAS  Google Scholar 

  106. Paul MA, McCarthy AE, Gibson N, et al. The impact of Malarone and primaquine on psychomotor performance. Aviat Space Environ Med 2003; 74(7): 738–45

    PubMed  CAS  Google Scholar 

  107. Leder K, Black J, O’Brien D, et al. Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2004; 39(8): 1104–12

    Article  PubMed  Google Scholar 

  108. Loutan L. Malaria: still a threat to travellers. Int J Antimicrob Agents 2003; 21(2): 158–63

    Article  PubMed  CAS  Google Scholar 

  109. Schlagenhauf P, Steffen R, Loutan L. Migrants as a major risk group for imported malaria in European countries. J Travel Med 2003; 10(2): 106–7

    Article  PubMed  Google Scholar 

  110. Castelli F, Matteelli A, Caligaris S, et al. Malaria in migrants. Parassitologia 1999; 41(1–3): 261–5

    PubMed  CAS  Google Scholar 

  111. Lalloo DG, Trevett AJ, Paul M, et al. Severe and complicated falciparum malaria in Melanesian adults in Papua New Guinea. Am J Trop Med Hyg 1996; 55(2): 119–24

    PubMed  CAS  Google Scholar 

  112. Ladhani S, El Bashir H, Patel VS, et al. Childhood malaria in East London. Pediatr Infect Dis J 2003; 22(9): 814–9

    Article  PubMed  Google Scholar 

  113. Cleary VA, Figueroa JI, Heathcock R, et al. Improving malaria surveillance in inner city London: is there a need for targeted intervention? Commun Dis Public Health 2003; 6(4): 300–4

    PubMed  CAS  Google Scholar 

  114. Schwartz E, Parise M, Kozarsky P, et al. Delayed onset of malaria: implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349(16): 1510–6

    Article  PubMed  CAS  Google Scholar 

  115. D’Acremont V, Landry P, Mueller I, et al. Clinical and laboratory predictors of imported malaria in an outpatient setting: an aid to medical decision making in returning travelers with fever. Am J Trop Med Hyg 2002; 66(5): 481–6

    PubMed  Google Scholar 

  116. Klement E, Chauveheid MP, Thellier M, et al. Subacute clinical forms of Plasmodium falciparum malaria in travelers receiving chloroquine-proguanil prophylaxis. Clin Infect Dis. 2001 Jul 1; 33(1): e1–2. Epub 2001 May 23

    Article  PubMed  CAS  Google Scholar 

  117. Wongsrichanalai C, Gasser Jr RA. Current status of malaria rapid diagnostic devices: an update. Trends Parasitol 2002; 18(3): 107–8

    Article  PubMed  Google Scholar 

  118. Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 2003; 19(3): 115–20

    Article  PubMed  CAS  Google Scholar 

  119. Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States (based on drugs currently available for use in the United States) [online]. Available from URL: http://www.cdc.gov/malaria/pdf/treatmenttable.pdf [Accessed 2005 Jul 26]

  120. Suh KN, Kain KC, Keystone JS. Malaria. CMAJ 2004 May 25; 170(11): 1693–702

    Article  PubMed  Google Scholar 

  121. Schlagenhauf P, Steffen R. Stand-by treatment of malaria in travellers: a review. J Trop Med Hyg 1994; 97(3): 151–60

    PubMed  CAS  Google Scholar 

  122. Schlagenhauf P, Steffen R, Tschopp A, et al. Behavioural aspects of travellers in their use of malaria presumptive treatment. Bull World Health Organ 1995; 73(2): 215–21

    PubMed  CAS  Google Scholar 

  123. Nothdurft HD, Jelinek T, Pechel SM, et al. Stand-by treatment of suspected malaria in travellers. Trop Med Parasitol 1995; 46(3): 161–3

    PubMed  CAS  Google Scholar 

  124. Whitty CJM, Armstrong M, Behrens RH. Self-testing for falciparum malaria with antigen-capture cards by travelers with symptoms of malaria. Am J Trop Med Hyg 2000; 63(5–6): 295–7

    PubMed  Google Scholar 

  125. Touze JE, Fourcade L, Peyron F, et al. Is halofantrine still advisable in malaria attacks? Ann Trop Med Parasitol 1997; 91(7): 867–73

    Article  PubMed  CAS  Google Scholar 

  126. McKeage K, Scott L. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs 2003; 63(6): 597–623

    Article  PubMed  CAS  Google Scholar 

  127. Giao PT, De Vries PJ, Hung LQ, et al. Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam. Ann Trop Med Parasitol 2003; 97(6): 575–80

    Article  PubMed  CAS  Google Scholar 

  128. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113(8): 1084–92

    PubMed  CAS  Google Scholar 

  129. Newton P, Proux S, Green M, et al. Fake artesunate in southeast Asia. Lancet 2001; 357(9272): 1948–50

    Article  PubMed  CAS  Google Scholar 

  130. Wernsdorfer WH. Coartemether (artemether and lumefantrine): an oral antimalarial drug. Expert Rev Anti Infect Ther 2004; 2(2): 181–96

    Article  PubMed  CAS  Google Scholar 

  131. Rendi-Wagner P, Noedl H, Wernsdorfer WH, et al. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop 2002; 81(2): 167–73

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The views in this paper are those of the authors and do not purport to reflect official policy of the US Department of the Army or the Department of Defence or the Australian Defence Health Service or any extant Australian Defence Force policy. Use of medications’ proprietary names should not be interpreted as a specific endorsement of any particular company’s product.

No funding was provided to the authors for producing this article. Dr Shanks has been an unpaid consultant for Glaxo-SmithKline within the past 2 years. Dr Edstein claims no potential conflicts of interest.

The authors thank Professor Karl H. Rieckmann for his critical review of the manuscript. We are grateful to Dr David Jacobus (Jacobus Pharmaceuticals Company) and Dr Dennis E. Kyle (Walter Reed Army Institute of Research) for permission to use unpublished information.

Author information

Authors and Affiliations

  1. Australian Army Malaria Institute, Brisbane, Queensland, Australia

    G. Dennis Shanks (US Army retired) & Michael D. Edstein

Authors
  1. G. Dennis Shanks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael D. Edstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Dennis Shanks.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shanks, G.D., Edstein, M.D. Modern Malaria Chemoprophylaxis. Drugs 65, 2091–2110 (2005). https://doi.org/10.2165/00003495-200565150-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565150-00003

Keywords

Search

Navigation